Finjuve is a topical finasteride spray used in the management of male androgenetic alopecia (male pattern hair loss).
It is a prescription-only medicine. This page is a reference to the published evidence for topical finasteride and lists providers that dispense Finjuve. It is not a clinic or pharmacy.
What Finjuve is, the supporting clinical evidence, current news, where it can be obtained, and prescriber-level information.
A plain-language overview of topical finasteride, how it acts on dihydrotestosterone, and what patients can expect from treatment.
Read overview 02 / 06A curated library of peer-reviewed studies on topical finasteride — pharmacokinetics, efficacy, safety and comparisons with oral therapy.
Browse studies 03 / 06Regulatory updates, research developments, expert commentary and press coverage relating to topical finasteride and male pattern hair loss.
View latest 04 / 06A searchable directory of authorised online clinics, pharmacies and telehealth providers that dispense Finjuve in the UK, Ireland and internationally.
Find a stockist 05 / 06Mechanism of action, pharmacokinetics, safety profile and prescribing references for dermatologists, GPs and prescribing pharmacists.
HCP resources 06 / 06Concise, evidence-based answers to the questions patients ask most often about Finjuve and topical finasteride.
Read FAQsFinasteride is a competitive inhibitor of type II 5-alpha reductase, reducing local conversion of testosterone into dihydrotestosterone (DHT) in the scalp.
Delivered as a cutaneous spray applied directly to the scalp, with the aim of acting locally on follicular DHT while limiting systemic exposure.
Studied for the management of male androgenetic alopecia (male pattern hair loss). Prescription status applies in most jurisdictions, including the UK and Ireland.
From the research library.
A multicentre, randomised, double-blind, parallel-group phase III trial reporting non-inferiority of a 0.25% topical finasteride spray versus oral 1 mg finasteride for change in target-area hair count, with reduced systemic DHT impact.
Read full textSystematic review of seven clinical trials concluding that topical finasteride significantly improved hair count and density compared with placebo, with a favourable adverse-event profile relative to oral therapy.
View on PubMedThe pivotal one-year, double-blind, placebo-controlled trial that established oral finasteride 1 mg/day as effective for male AGA — the foundational evidence base on which subsequent topical research builds.
View sourceOnline clinics, pharmacies and telehealth providers that dispense Finjuve, by country and provider type.
It does not replace clinical assessment or advice from a qualified healthcare professional. Topical finasteride is a prescription medicine and should only be used under appropriate medical supervision.